Thursday, August 06, 2026
New Study Finds Bacterial Infections Affect About 1 in 20 Hospitalized Adults With Firearm Injuries
A new study from researchers at the University of Maryland School of Medicine (UMSOM) found that bacterial infections develop in approximately 5 percent of adults hospitalized with firearm injuries, with most infections occurring during the initial hospitalization rather than after patients return home. The findings were published Aug. 3 in JAMA Network Open as a research letter.
Thursday, July 30, 2026
Clinicians Should Include E-Cigarettes in Smoking Cessation Discussions with Tobacco Smoking Patients, New Consensus Recommendations Find
Clinicians should include nicotine-containing e-cigarettes alongside other evidence-based options for quitting cigarette smoking in conversations with adult patients, according to a new Special Communication published today in JAMA that is co-authored by a University of Maryland School of Medicine faculty member. The group of 24 tobacco treatment and addiction experts was convened by the Society for Research on Nicotine and Tobacco (SRNT) and was tasked with reviewing the latest literature to make recommendations directed at healthcare practitioners.
Thursday, July 30, 2026
Nationally Recognized Pediatric Oncologist Named Director of Pediatric, Adolescent and Young Adult Cell and Gene Therapy Program
Nirali N. Shah, MD, MHSc, a nationally-recognized pediatric oncologist at the National Cancer Institute (NCI), has been appointed Professor and Director of the Pediatric/Adolescent and Young Adult Cell and Gene Therapy Program at University of Maryland School of Medicine. She will also serve as Associate Director for Translational Research for the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) .
Wednesday, July 29, 2026
UM School of Medicine Establishes Two Endowed Professorships in Gene & Cell Therapy and Pediatric Cardiac Surgery through Maryland E-Nnovation Awards
The University of Maryland, Baltimore (UMB) has been awarded $1.5 million in matching funds from the Maryland E-Nnovation Initiative Fund (MEIF), administered by the Maryland Department of Commerce, to establish two new endowed professorships at the University of Maryland School of Medicine (UMSOM). Combined with $1.5 million in matching qualified funding from the university, the awards total $3 million and will support the recruitment of two physician-scientists to advance research and clinical innovation in gene and cell therapy and pediatric cardiac surgery, UMSOM Dean Mark T. Gladwin, MD, announced today.
Friday, July 24, 2026
Internationally Recognized Expert Leads University of Maryland School of Medicine Program in Sickle Cell Disease
Enrico M. Novelli, MD, MS, has been named Director of the University of Maryland School of Medicine (UMSOM) Program in Sickle Cell Disease and a Professor in the Department of Medicine, Division of Hematology/Oncology. An internationally recognized expert in sickle cell disease, he will treat patients at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) and serve as Chief of the University of Maryland Medical System (UMMS) Sickle Cell Disease and Classical Hematology Network, a new initiative to expand access to care for patients with sickle cell disease across Maryland.
Wednesday, July 22, 2026
Cruise Ship Hantavirus Outbreak Highlights Need for Clear Public Health Communication and Global Disease Preparedness
A small outbreak of a rare hantavirus on a cruise ship earlier this year captured worldwide attention and sparked concerns about a possible new pandemic. But according to a new University of Maryland School of Medicine (UMSOM) commentary published in JAMA Internal Medicine, the outbreak posed little risk to the general public and offers important lessons about how health officials, scientists, and the media should communicate during emerging disease events.
Friday, July 10, 2026
CVD and Collaborators Launch Study to Better Understand Immune Responses to Lassa Fever
The University of Maryland School of Medicine Center for Vaccine Development and Global Health (CVD), has announced the launch of a research study to understand how Lassa fever survivors fight and overcome Lassa virus infection. The study, titled “Identification and Immunologic Characterization of Adult Lassa Fever Survivors in Nigeria”, is a collaboration between CVD, The Institute of Human Virology Nigeria (IHVN) International Research Center of Excellence (IRCE), and the Abubakar Tafawa Balewa University Teaching Hospital (ATBUTH) in Bauchi State.
Wednesday, July 08, 2026
UMSOM's Bradley A. Maron, MD, Named Editor-in-Chief of Circulation, the American Heart Association's Flagship Journal
Bradley A. Maron, MD, Senior Associate Dean for Precision Medicine at the University of Maryland School of Medicine (UMSOM), has been named editor-in-chief of Circulation, the American Heart Association's flagship peer-reviewed journal and one of the world's leading scientific publications in cardiovascular medicine. In his new role, Dr. Maron will help shape the journal's editorial direction and its ongoing publication of rigorous, practice-changing science for clinicians and researchers worldwide.
Monday, June 29, 2026
Kahlert Institute for Addiction Medicine Inaugurates New Facility to Develop Treatments for Addiction
The University of Maryland School of Medicine (UMSOM) celebrated a major milestone on June 2 with a ribbon cutting ceremony to officially inaugurate 34,000 square feet of newly renovated space for the Kahlert Institute for Addiction Medicine. Located on the fifth floor of the Health Sciences Research Facility (HSRF) III building on the school’s Baltimore campus, the new space brings together operations, basic science, and clinical research laboratories in a unified environment designed to accelerate breakthroughs in addiction science.
Friday, June 12, 2026
Researchers Identify Target with Potential to Improve CAR T-Cell Therapy Response in Patients with Blood Cancers
University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.